Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
OpenAI Restricts Astra AI Over Cyberattack Risks 
NEW YORK, March 02, 2018 -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will be presenting at two upcoming investor conferences. Presentation details are as follows:
- The Raymond James & Associates’ 39th Annual Institutional Investors Conference, being held at the JW Marriott Orlando Grande Lakes in Orlando, Florida. The presentation is scheduled to take place on Tuesday March 6, 2018 at 2:50pm ET.
- The Cowen 38th Annual Health Care Conference, being held at the Boston Marriott Copley Place in Boston, Massachusetts. The presentation is scheduled to take place on Monday March 12, 2018 at 1:30pm ET.
A live webcast of each presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.
CONTACT:
Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]
